CA2064481A1 - Method of producing .alpha.,.beta.-unsaturated ketolactones - Google Patents

Method of producing .alpha.,.beta.-unsaturated ketolactones

Info

Publication number
CA2064481A1
CA2064481A1 CA2064481A CA2064481A CA2064481A1 CA 2064481 A1 CA2064481 A1 CA 2064481A1 CA 2064481 A CA2064481 A CA 2064481A CA 2064481 A CA2064481 A CA 2064481A CA 2064481 A1 CA2064481 A1 CA 2064481A1
Authority
CA
Canada
Prior art keywords
beta
alpha
producing
ketolactones
unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2064481A
Other languages
French (fr)
Other versions
CA2064481C (en
Inventor
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
Ryuji Ueno
Tomio Oda
R-Tech Ueno, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryuji Ueno, Tomio Oda, R-Tech Ueno, Ltd. filed Critical Ryuji Ueno
Publication of CA2064481A1 publication Critical patent/CA2064481A1/en
Application granted granted Critical
Publication of CA2064481C publication Critical patent/CA2064481C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention provides a method of preparing .alpha.,.beta.-unsaturated ketolactones which are useful in the production of prostaglandins having one or more halogen substituent(s) at position 16 or 17 in high yield, in which, a dimethyl (2-oxoalkyl) phosphonate having one or more halogen substituents (as a starting material) is reacted with a bicyclolactone aldehyde in the presence of an alkali metal hydride and a zinc compound.
CA002064481A 1991-04-04 1992-03-31 Method of producing .alpha.,.beta.-unsaturated ketolactones Expired - Fee Related CA2064481C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP71483/1991 1991-04-04
JP7148391 1991-04-04

Publications (2)

Publication Number Publication Date
CA2064481A1 true CA2064481A1 (en) 1992-10-05
CA2064481C CA2064481C (en) 1996-12-24

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002064481A Expired - Fee Related CA2064481C (en) 1991-04-04 1992-03-31 Method of producing .alpha.,.beta.-unsaturated ketolactones

Country Status (11)

Country Link
US (1) US5229529A (en)
EP (1) EP0507625B1 (en)
JP (1) JPH089608B2 (en)
KR (1) KR970003125B1 (en)
AT (1) ATE141921T1 (en)
CA (1) CA2064481C (en)
DE (1) DE69213067T2 (en)
DK (1) DK0507625T3 (en)
ES (1) ES2093776T3 (en)
GR (1) GR3020903T3 (en)
TW (1) TW197439B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT643051E (en) * 1992-09-30 2000-06-30 R Tech Ueno Ltd PROCESS OF PRODUCTION OF ALPHA, BETA-INSATURATED CETONAS
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP4358940B2 (en) * 1999-08-26 2009-11-04 丸善石油化学株式会社 Polymerizable compound and polymer having cyclohexanelactone structure
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
WO2002072150A2 (en) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
JP2004532847A (en) * 2001-04-20 2004-10-28 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア Micellar drug delivery system for hydrophobic drugs
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (en) * 2002-05-08 2003-11-20 Martin Foerster Method for determining an amount of liquid food drunk by animals
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ATE457716T1 (en) 2002-12-30 2010-03-15 Angiotech Int Ag RELEASE OF ACTIVE INGREDIENTS FROM QUICK-GELLING POLYMER COMPOSITION
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CA2819844C (en) * 2006-02-07 2015-09-15 R-Tech Ueno, Ltd. Prostaglandin derivatives
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
ATE519511T1 (en) 2006-06-30 2011-08-15 Cook Inc METHOD FOR PRODUCING AND MODIFYING TAXAN COATINGS FOR IMPLANTABLE MEDICAL DEVICES
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US9198893B2 (en) 2008-05-22 2015-12-01 Galera Labs, Llc Combination antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
ES2477552T3 (en) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
WO2010083597A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc Compounds and methods for producing a conjugate
PT2956175T (en) 2013-02-15 2017-12-26 Univ California Chimeric antigen receptor and methods of use thereof
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PL3107899T3 (en) 2014-02-19 2021-01-25 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
JP6877049B2 (en) 2015-09-25 2021-05-26 ゼットワイ セラピューティクス インク．Ｚｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug formulation based on granules containing polysaccharide-vitamin conjugate
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (en) 2015-12-30 2022-04-11 杏國新藥股份有限公司 Treatment of breast cancer
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
JP7109427B2 (en) 2016-06-01 2022-07-29 セルヴィエ アイピー ユーケー リミテッド Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
MX2019008503A (en) 2017-01-18 2019-09-13 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
JP2021530507A (en) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． Conjugates for delivering anticancer drugs to nerve cells, their usage and manufacturing methods
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022520220A (en) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク Recombinant vaccinia virus and how to use it
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
BR112022011158A2 (en) 2019-12-12 2022-08-30 Ignite Immunotherapy Inc VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOF
CA3164608A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4182335A2 (en) 2020-07-14 2023-05-24 Pfizer Inc. Recombinant vaccinia virus
KR20230061429A (en) 2020-09-02 2023-05-08 켄조케티 바이오테크놀러지 인코포레이티드 Anti-ABCC1 Antibodies and Uses Thereof
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (en) * 1976-01-08 1977-06-28
DE2655004C3 (en) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Process for the production of bicyclic lactones
DE3574470D1 (en) * 1985-09-18 1990-01-04 Upjohn Co Stereoselective reduktion.
JPS62153259A (en) * 1985-12-26 1987-07-08 Sagami Chem Res Center (2-chloro-3-oxo-1-alkenyl)-bicyclo(3.3.0)octene derivative and production thereof
DE3620442A1 (en) * 1986-06-18 1987-12-23 Merck Patent Gmbh KETOLACTONE
AU2130288A (en) * 1987-09-04 1989-03-31 Upjohn Company, The Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
EP0507625A1 (en) 1992-10-07
CA2064481C (en) 1996-12-24
GR3020903T3 (en) 1996-11-30
DK0507625T3 (en) 1996-09-16
EP0507625B1 (en) 1996-08-28
JPH089608B2 (en) 1996-01-31
JPH0592965A (en) 1993-04-16
ES2093776T3 (en) 1997-01-01
ATE141921T1 (en) 1996-09-15
KR970003125B1 (en) 1997-03-14
DE69213067D1 (en) 1996-10-02
US5229529A (en) 1993-07-20
KR920019771A (en) 1992-11-20
DE69213067T2 (en) 1997-01-16
TW197439B (en) 1993-01-01

Similar Documents

Publication Publication Date Title
CA2064481A1 (en) Method of producing .alpha.,.beta.-unsaturated ketolactones
HU9301296D0 (en) Method for producing pyrimidine compounds
AU7116691A (en) Process for the preparation of oxetanones
EP0343944A3 (en) Process for making 1,3-diols from epoxides
CA2032278A1 (en) Multistep synthesis of hexafluoropropylene
AU2628784A (en) Polyarylnitrile polymers
ES2122905A1 (en) Synthesis of 9-deoxo- 9a-aza 11,12-deoxy- 9a-methyl-9a-homoerythromycin A 11,12- hydrogenorthoborate dihydrate
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
CA2248953A1 (en) Novel benzofuranone derivatives and process for producing the same
ES8703150A1 (en) New B-Carboline-3-oxadiazolyl derivatives, method of preparing the same and their use.
CA2044498A1 (en) Process for the preparation of dialkyl, pyridine-2,3-dicarboxylates and derivatives thereof from dialkyl dichlorosuccinate
CA2158130A1 (en) Process and Intermediates for Preparing Azabicyclo(2.2.2)Octan-3-Imines
HU9200771D0 (en) Process for the production of aryl-1,2,4-triazolyn-5-on derivatives
CA2076886A1 (en) Method for production of 2-amino-6-halogenopurine and synthesis intermediate therefor
CA2067341A1 (en) Method for synthesis of prostaglandin derivatives
EP0147472A4 (en) 4-chloro-4-methyl-5-methylene-1,3-dioxolan-2-one.
EP0268273A3 (en) Process for the preparation of 2-substituted-1,4-dihydro-pyridines
CA2353680A1 (en) Process for the production of cyclene
EP0519083A4 (en) Process for producing hexahydropyridazine-1,2-dicarboxylic acid derivative
CA2068880A1 (en) Aqueous synthesis of 2-halo-4,6-dinitroresorcinol and 4,6-diaminoresorcinol
IT1189273B (en) SINGLE STAGE FERMENTATION PROCEDURE FOR THE PREPARATION OF 9-HYDROXY-3-BONE-4,17 (20) -PREGNADIEN-20-CARBOXYLIC ACID, USEFUL AS INTERMEDIATE FOR THE PRODUCTION OF STERROIDS
WO1988002364A3 (en) Process for the production of ethane derivatives
CA2060045A1 (en) Process for preparing perhalogenated olefins
EP0316185A3 (en) N-cyanomethyl-2-pyridinone insecticides
EP0267605A3 (en) Novel intermediate compounds in a process for producing 16-phenoxy- and 16-substituted phenoxy-9-keto-prostatrienoic acid derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed